Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
CRO Deals Are Hot and About to Get Hotter
The need for outsourced research and development services has caused a huge increase in the number of deals for contract research organizations (CROs) and contract manufacturing organizations (CMOs). In 2016, 36 acquisitions of CROs and CMOs were announced in 2016, a 157% increase from 2015’s total of 14 deals, according to data reported in the Health Care Services Acquisition Report, 2017. That pace is picking up. In the first six weeks of 2017, six CRO/CMO deals have been announced,with even more to come. Last week, Reuters reported that Laboratory Corp. of America Holdings (NYSE: LH) is in talks to buy Pharmaceutical Product Development LLC (PPD), a portfolio company of Hellman &... Read More »Digital Health Off to a Strong Start in 2017
The eHealth sector has started off the New Year at an even faster pace than last year. In January 2017, 21 eHealth deals have been announced, a 91% increase from January 2016’s eHealth deals. The sector ended 2016 with 155 transactions Of course, there was the previously mentioned takeover of CoverMyMeds LLC by McKesson Corporation (NYSE: MCK), there have been a few other notable mentions. On January 4, 2017, Castlight Health Inc. (NYSE: CSLT) spent $135 million of its shares to acquire Jiff Inc. The company provides a HIPAA-compliant social network and digital health platform, which serves as a central hub for well-being and other benefit programs, with a single point of access for... Read More »Recent Health Care Deals, week ending 02.03.2017
AcquirerTargetPrice Piramal Critical Care Inc. Mallinckrodt's intrathecal therapy business$203 million Incyte CorporationLicense to CB-1158$45 million CareTrust REIT, Inc.2 memory care companies$26.1 million Diplomat Pharmacy, Inc. Affinity Biotech Inc. $16 million Regional hospital systemsWingate at Melrose$3.6... Read More »
Varian Spins Off Varex Imaging Systems
A medical imaging company is born. Or, rather, another medical imaging company goes public. Varian Medical Systems Inc. (NYSE: VAR) paid $276 million for the medical imaging business of PerkinElmer (NYSE: PKI) back in December 2016. That business, based in Santa Clara, California, supplies flat panel x-ray detectors that serve as components for industrial, medical and dental x-ray imaging systems. That deal was part of Varian’s plan to spin off its Imaging Components business. That feat was accomplished in January 2017, with the launch of Varex Imaging Corporation (NASDAQ: VREX), with a market cap of $1.09 billion. Under the terms of the separation, Varian stockholders received 0.4... Read More »
MEDNAX Moves into Radiology
It’s been a while since MEDNAX (NYSE: MD) surprised the healthcare industry with its $500 million acquisition of Virtual Radiologic Corporation (NASDAQ: VRAD). Since May 2015, in fact. Consider the wait over. The MEDNAX M&A juggernaut is rolling into the radiology arena. The acquisition of vRad added approximately 350 radiologists to MEDNAX’ payroll back then, at an average of $1.4 million per radiologist. It also added a telemedicine component, which was previously missing from MEDNAX’ dealings with hospitals on behalf of its anesthesiology and neonatology divisions. Essentially, vRad physicians read and interpret more than 5 million diagnostic imaging studies... Read More »Mallinckrodt Divests to Pursue Specialty Pharma Niche
The latest watchword for the pharmaceutical industry is “specialization,” as in “specialization is a safer bet than diversification.” A lot of big-name pharma companies are divesting their non-core businesses in order to target specific therapeutics and disease areas. The most recent example is Mallinckrodt plc (NYSE:MNK), which has sold off approximately $893 million of its assets in the past six months, in order to focus on its specialty pharmaceutical platforms in autoimmune and rare diseases. In August 2016, Mallinckrodt sold its nuclear imaging business for $690 million to IBA Molecular, a global manufacturer and distributor of... Read More »JNJ Bolsters Its Pipeline with Actelion Acquisition
It took a while, but Johnson & Johnson (NYSE: JNJ) finally bagged Swiss-based Actelion Ltd. (SIX: ATLN), Europe’s biggest biotech company. The company had been in play since August 2016, when J&J began negotiations, but eventually bowed out after offering $260 per share, or $28 billion. Sanofi S.A. (NYSE: SNY) moved in and by mid-December, Bloomberg reported, the two parties were discussing a price of $275 per share, valuing Actelion at $29.6 billion. For both suitors, a deal with Actelion would boost their aging pipelines. Actelion, which was formed in 1997 as a spin-out from Roche (SIX: RO), had developed a strong portfolio of drugs for pulmonary arterial hypertension, a... Read More »Recent Health Care Deals, week ending 01.27.2017
AcquirerTargetPrice Johnson & JohnsonActelion Ltd. $30.1 billion McKesson CorporationCoverMyMeds$1.4 billion Celgene CorporationDelinia, Inc. $300 million Generex Biotechnology Corp.Emmaus Life Sciences, Inc. $225 million Intrexon CorporationGenVec Inc. $15.9... Read More »Francisco Partners Exits CoverMyMeds for $1.1 Billion
Francisco Partners and McKesson Corp. (NYSE: MCK) are swapping companies again. Back in October 2013, the technology-focused private equity firm acquired McKesson Automation, which offers integrated pharmacy automation products for hospitals and health systems, thus streamlining the delivery of medications. Financial terms were not disclosed. In January 2017, McKesson acquired CoverMyMeds, LLC from Francisco Partners for $1.1 billion, and another $300 million if the company met future financial targets. To make things even cozier, McKesson and CoverMyMeds have partnered together to work with pharmacies since 2010. CoverMyMeds provides electronic prior authorization... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
